Granules India Limited (NSE:GRANULES)
767.95
-21.90 (-2.77%)
Jun 8, 2026, 3:30 PM IST
Granules India Revenue
In the fiscal year ending March 31, 2026, Granules India had annual revenue of 53.66B INR with 19.73% growth. Granules India had revenue of 14.71B in the quarter ending March 31, 2026, with 22.81% growth.
Revenue
53.66B
Revenue Growth
+19.73%
P/S Ratio
3.54
Revenue / Employee
13.20M
Employees
4,066
Market Cap
190.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 53.66B | 8.84B | 19.73% |
| Mar 31, 2025 | 44.82B | -247.59M | -0.55% |
| Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
| Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
| Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emcure Pharmaceuticals | 92.04B |
| Piramal Pharma | 88.69B |
| Alembic Pharmaceuticals | 73.45B |
| Gland Pharma | 64.31B |
| Ajanta Pharma | 54.53B |
| Strides Pharma Science | 48.59B |
| NATCO Pharma | 40.78B |
| Wockhardt | 33.73B |
Granules India News
- 5 days ago - Granules India subsidiary receives USFDA EIR for Chantilly facility - Business Upturn
- 12 days ago - Why are Granules India shares up nearly 5% today? Block deal worth 15.3 lakh shares triggers buying interest - Business Upturn
- 5 weeks ago - Granules India Transcript: Q4 25/26 - Transcripts
- 5 weeks ago - Granules India Quarterly report: Q4 2026 - Filings
- 5 weeks ago - Granules India Slides: Q4 2026 - Filings
- 5 weeks ago - Granules India reports 23% YoY revenue growth in Q4FY26 - Business Upturn
- 2 months ago - Granules India completes cGMP audit at Chantilly site with four FDA observations - Business Upturn
- 2 months ago - Granules India subsidiary receives VAI classification after US FDA inspection - Business Upturn